Story perspectives
Arkin Capital Raises $100M for Biotech Investments
1/14/2026
47 8
1 of 1
Story summary
- Arkin Capital has raised $100 million for Arkin Bio Ventures III.
- Arkin Bio Ventures III is an early-stage biotech fund backed by Israeli institutional investors.
- The fund will invest in companies up to the proof-of-concept stage, focusing on oncology and gene therapy, according to Dr. Pini Orbach.
- Skylark Bio is the first investment.
- Skylark Bio will enter clinical trials for a gene editing therapy for deaf children.
